Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-2b + nucleoside analog + Bacteroides fragilis + branched-chain amino acids
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Small Molecules, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Oral
01
Overview
This combination therapeutic regimen is being investigated for the treatment of chronic hepatitis B virus (HBV) infection. It consists of standard-of-care antiviral therapy—peginterferon alfa-2b (an immune modulator) and a nucleoside analog (a viral polymerase inhibitor)—supplemented with the probiotic *Bacteroides fragilis* and branched-chain amino acids (BCAA). The rationale behind this combination is to enhance HBsAg clearance by modulating the gut microbiota and providing nutritional support to improve the host's immune response against the virus. The study is being conducted by the First Affiliated Hospital of Fujian Medical University.
- Other names
- PegIFNα2b + nucleoside analog + Bacteroides fragilis + branched-chain amino acids
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on peginterferon alfa-2b + nucleoside analog + Bacteroides fragilis + branched-chain amino acids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-2b + nucleoside analog + Bacteroides fragilis + branched-chain amino acids.